Today's Trend
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is moving higher after HC Wainwright reiterated a Buy rating and $21 price target while raising several earnings estimates following the company’s recent Q1 update and earnings call.
- HC Wainwright lifted near-term EPS estimates for Q2 2026 to ($0.11) from ($0.12), suggesting modestly better expected profitability. Trevi Therapeutics Q1 2026 Earnings Call Transcript
- The firm also increased its Q3 2026 EPS estimate to ($0.14) from ($0.17), Q4 2026 to ($0.15) from ($0.17), and FY2026 to ($0.47) from ($0.54).
- HC Wainwright kept a bullish long-term view, raising its FY2027 estimate to ($0.57) from ($0.63) and FY2028 to ($0.63) from ($0.66), while maintaining the same $21 price target.
- The analyst trimmed its FY2029 estimate to $0.70 from $0.79 in one report, but the overall tone remained constructive.
- Trevi recently reported a Q1 loss of ($0.09) per share, slightly wider than expectations, so the stock’s move appears driven more by improved forward estimates and analyst confidence than by the latest earnings print.
Overall, TRVI appears to be gaining support from higher earnings forecasts and a reaffirmed bullish analyst stance, which is helping offset the company’s still-loss-making near-term outlook.